- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Medical simulation.
Displaying page 1 of 1.
EudraCT Number: 2015-003534-27 | Sponsor Protocol Number: CIGE025B1301 | Start Date*: 2016-02-16 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic ... | ||
Medical condition: Allergic asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-004457-23 | Sponsor Protocol Number: 29BRC21.0255 | Start Date*: 2022-01-24 | ||||||||||||||||
Sponsor Name:CHU de Brest | ||||||||||||||||||
Full Title: Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography | ||||||||||||||||||
Medical condition: Aortic stenosis TAVI Cardiac conduction disorders Pacemaker | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000086-17 | Sponsor Protocol Number: AK901 | Start Date*: 2020-08-06 | ||||||||||||||||||||||||||
Sponsor Name:Akari Therapeutics Plc | ||||||||||||||||||||||||||||
Full Title: Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy | ||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003956-30 | Sponsor Protocol Number: CHDR1429 | Start Date*: 2014-10-13 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: A single-centre randomized double-blind, double-dummy, placebo-controlled, four-way crossover study in healthy subjects to investigate the effect of ethanol 0.5 and 1.0 g/L and alprazolam 1 mg on a... | ||
Medical condition: A total of 24 healthy subjects, both male and female, will be enrolled into the study following satisfactory completion of a screening visit where eligibility for the study will be checked. Subje... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000075-39 | Sponsor Protocol Number: C4671026 | Start Date*: 2022-04-05 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITAL... | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) BG (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000088-28 | Sponsor Protocol Number: FHCRH2448 | Start Date*: 2011-08-16 | |||||||||||
Sponsor Name:Fred Hutchinson Cancer Research Center | |||||||||||||
Full Title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablat... | |||||||||||||
Medical condition: Graft versus host disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002093-42 | Sponsor Protocol Number: SHP643-301 | Start Date*: 2020-02-04 | ||||||||||||||||
Sponsor Name:Shire (Shire is now part of Takeda) | ||||||||||||||||||
Full Title: SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (... | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001466-21 | Sponsor Protocol Number: 61364 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Erasmus MC University Medical Center | |||||||||||||
Full Title: Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands. The effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither. | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008202-52 | Sponsor Protocol Number: REMARC | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE | |||||||||||||
Medical condition: Diffuse Large B Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) PT (Completed) ES (Completed) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000422-55 | Sponsor Protocol Number: CINC424F12201 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic st... | |||||||||||||
Medical condition: treatment naïve aGvHD grades II-IV or steroid-refractory aGvHD grades II-IV | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) BE (Completed) FR (Completed) DE (Completed) ES (Temporarily Halted) NL (Not Authorised) IT (Completed) DK (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
